Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director | June 28, 2022 | June 30, 2022 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27 | Direct | 20,000 |
Reported balance
After 2022-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Spyre Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Row 2 · 2026-08-07 · Sale · Disposed 5,000 · Balance 0 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | IndirectBy Sessions LLC | 19,360 |
Reported balance
After 2026-08-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-07 · Sale · Disposed 8,000 · Balance 19,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | IndirectBy Sessions LLC | 9,360 |
Reported balance
After 2026-08-07 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-08-07 · Sale · Disposed 10,000 · Balance 9,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2033-11-22 | Direct | 45,000 |
Reported balance
After 2026-08-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-07 · Exercise / conversion · Disposed 5,000 · Balance 45,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blueprint Medicines Corp
Report date July 17, 2025 · Filed July 21, 2025
Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-07-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-07-17 · Disposition to issuer · Disposed 5,777 · Balance 144,755 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 144,755 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-17 · Disposition to issuer · Disposed 92,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-17 · Disposition to issuer · Disposed 170,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-17 · Disposition to issuer · Disposed 110,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-17 · Disposition to issuer · Disposed 90,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-17 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001636282-26-000102 · wk-form4_1786411908.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 5,000 shares Expires 2033-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5 · derivative.exercise_date: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 10,000 | $104.68 | $1,046,800.00 |
DisclosureSEC source: 0001636282-26-000102 · wk-form4_1786411908.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Sessions LLC Disclosed balance after: 9,360 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 8,000 | $104.38 | $835,040.00 |
DisclosureSEC source: 0001636282-26-000102 · wk-form4_1786411908.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Sessions LLC Disclosed balance after: 19,360 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,000 | $104.47 | $522,350.00 |
DisclosureSEC source: 0001636282-26-000102 · wk-form4_1786411908.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 5,000 | $10.39 | $51,950.00 |
DisclosureSEC source: 0001636282-26-000102 · wk-form4_1786411908.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 6,068 | $0.00 Strike: $99.87 | $0.00 |
DisclosureSEC source: 0001193125-26-283136 · ownership.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 Underlying: Common Stock · 6,068 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:56 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 8,026 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001636282-26-000068 · wk-form4_1780091789.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,026 Underlying: Common Stock · 8,026 shares Expires 2036-05-27 F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001193125-25-311505 · ownership.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,252 | $90.30 | $203,363.48 |
DisclosureSEC source: 0001193125-25-311505 · ownership.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,748 | $89.32 | $245,459.60 |
DisclosureSEC source: 0001193125-25-311505 · ownership.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,252 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $89.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,000 | $14.18 | $70,900.00 |
DisclosureSEC source: 0001193125-25-311505 · ownership.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 11:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-25-238130 · ownership.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F3 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 11:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,000 | $59.19 | $295,949.00 |
DisclosureSEC source: 0001193125-25-238130 · ownership.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 11:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,000 | $10.34 | $51,700.00 |
DisclosureSEC source: 0001193125-25-238130 · ownership.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,570 | Not disclosed Strike: $106.14 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 10 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,570 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,300 | Not disclosed Strike: $63.66 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 9 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $61.31 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 8 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $100.13 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 7 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $54.13 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 110,500 | Not disclosed Strike: $86.60 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $81.44 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerStock Option (Right to Buy) · Derivative | 92,500 | Not disclosed Strike: $36.05 | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | OtherCommon Stock | 144,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:44 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Disposition to issuerCommon Stock | 5,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-069377 · tm2521348-1_4seq1.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,755 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 01:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $46.47 | $0.00 |
DisclosureSEC source: 0000950170-25-090585 · ownership.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 16:28 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 3,902 | $128.12 | $499,924.24 |
DisclosureSEC source: 0001415889-25-018086 · form4-06242025_080659.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,532 F1 · shares: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,349 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0000950170-25-081198 · ownership.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 6,349 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,349 | $49.00 | $311,101.00 |
DisclosureSEC source: 0000950170-25-081198 · ownership.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 6,349 | $10.34 | $65,648.66 |
DisclosureSEC source: 0000950170-25-081198 · ownership.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0001636282-25-000064 · wk-form4_1748896459.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:20 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $36.05 | $0.00 |
DisclosureSEC source: 0001415889-25-014862 · form4-05292025_040502.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 5,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:20 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 650 | $101.93 | $66,254.50 |
DisclosureSEC source: 0001415889-25-014862 · form4-05292025_040502.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,630 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $101.53 to $102.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:20 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,350 | $101.02 | $439,437.00 |
DisclosureSEC source: 0001415889-25-014862 · form4-05292025_040502.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,280 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $100.42 to $101.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:20 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 5,000 | $36.05 | $180,250.00 |
DisclosureSEC source: 0001415889-25-014862 · form4-05292025_040502.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:36 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $36.05 | $0.00 |
DisclosureSEC source: 0001415889-25-008112 · form4-03142025_080315.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 7,500 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:36 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,800 | $88.37 | $159,066.00 |
DisclosureSEC source: 0001415889-25-008112 · form4-03142025_080315.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,396 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.22 to $88.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:36 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,700 | $87.62 | $499,434.00 |
DisclosureSEC source: 0001415889-25-008112 · form4-03142025_080315.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,196 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.22 to $88.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:36 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 7,500 | $36.05 | $270,375.00 |
DisclosureSEC source: 0001415889-25-008112 · form4-03142025_080315.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 05, 2025 Filed Mar 17, 2025 16:26 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,766 | $88.80 | $512,020.80 |
DisclosureSEC source: 0001415889-25-008211 · form4-03172025_080359.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,630 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:53 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $36.05 | $0.00 |
DisclosureSEC source: 0001415889-25-001989 · form4-01242025_120158.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:53 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 200 | $110.61 | $22,122.00 |
DisclosureSEC source: 0001415889-25-001989 · form4-01242025_120158.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,396 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:53 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 7,400 | $109.92 | $813,408.00 |
DisclosureSEC source: 0001415889-25-001989 · form4-01242025_120158.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,596 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.55 to $110.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:53 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 7,561 | $109.11 | $824,980.71 |
DisclosureSEC source: 0001415889-25-001989 · form4-01242025_120158.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,996 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.55 to $109.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:53 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 10,000 | $36.05 | $360,500.00 |
DisclosureSEC source: 0001415889-25-001989 · form4-01242025_120158.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 18:04 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $36.05 | $0.00 |
DisclosureSEC source: 0001415889-25-001507 · form4-01152025_110148.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 18:04 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,000 | $102.28 | $511,400.00 |
DisclosureSEC source: 0001415889-25-001507 · form4-01152025_110148.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,557 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $102.00 to $102.44 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 18:04 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 5,000 | $36.05 | $180,250.00 |
DisclosureSEC source: 0001415889-25-001507 · form4-01152025_110148.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 16:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $36.05 Strike: $36.05 | $540,750.00 |
DisclosureSEC source: 0001415889-24-029971 · form4-12202024_041206.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 16:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 2,100 | $91.96 | $193,116.00 |
DisclosureSEC source: 0001415889-24-029971 · form4-12202024_041206.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,557 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.84 to $92.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 16:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 3,800 | $91.15 | $346,370.00 |
DisclosureSEC source: 0001415889-24-029971 · form4-12202024_041206.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,657 F1 · kind: Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.79 to $91.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.